

JOURNAL OF MEDICINAL CHEMISTRY

© Copyright 1995 by the American Chemical Society

Volume 38, Number 4

February 17, 1995

Communications to the Editor

Inhibitors of HIV-1 Protease Containing the Novel and Potent (*R*)-(Hydroxyethyl)sulfonamide Isostere

Michael L. Vazquez,^{*,†} Martin L. Bryant,[‡]
Michael Clare,[†] Gary A. DeCrescenzo,[‡]
Elizabeth M. Doherty,[‡] John N. Freskos,[‡]
Daniel P. Getman,[‡] Kathryn A. Houseman,[†]
Janet A. Julien,[†] GERALYN P. KOCAN,[†]
Richard A. Mueller,[†] Huey-Sheng Shieh,[§]
William C. Stallings,[§] Roderick A. Stegeman,[§] and
John J. Talley[‡]

Searle Discovery Research, 4901 Searle Parkway, Skokie, Illinois 60077, Searle Discovery Research, 700 Chesterfield Village Parkway, St. Louis, Missouri 63198, and Protein Crystallography Group, 700 Chesterfield Village Parkway, St. Louis, Missouri 63198

Received November 11, 1994

Replication of the HIV virus requires processing of the proteins encoded by the *gag* and *gag-pol* genes by a virally encoded aspartyl protease (HIV protease).¹ As such, inhibition of the HIV protease offers an attractive target for the treatment of acquired immunodeficiency syndrome (AIDS).²⁻⁴ Numerous examples of potent inhibitors of this enzyme have been reported.⁵⁻⁷ We have previously reported the discovery of a series of potent HIV-1 protease inhibitors containing the (*R*)-(hydroxyethyl)urea isostere.⁸ We now report a novel series of highly potent HIV-1 protease inhibitors incorporating the (*R*)-(hydroxyethyl)sulfonamide isostere. While sulfur-⁹ and phosphorus-based¹⁰ isosteres have been reported previously, the sulfur or phosphorus groups were incorporated as scissile bond replacements. The (*R*)-(hydroxyethyl)sulfonamides described here contain the sulfamido moiety in place of the P1'P2' amide linkage.

A variety of (hydroxyethyl)sulfonamides were synthesized to determine the optimal binding of this group within the S1' and S2' subsites and the preferred stereochemistry of the hydroxyl group.

[†] Searle Discovery Research, Skokie, IL.

[‡] Searle Discovery Research, St. Louis, MO.

[§] Protein Crystallography Group.


Table 1. HIV-1 Protease Inhibitors IC₅₀ and K_i Values

compd	R ₁	R ₂	R ₃	-OH ^a	IC ₅₀ (nM) ^b	K _i (nM)
4	CH ₃	CH ₂ CH ₂ CH(CH ₃) ₂	Cbz ^c	R	3200	1872
5	<i>n</i> -C ₃ H ₇	CH ₂ CH ₂ CH(CH ₃) ₂	Cbz	R	210	128
6a	C ₆ H ₅	CH ₂ CH ₂ CH(CH ₃) ₂	Cbz	R	16	10
6b	C ₆ H ₅	CH ₂ CH ₂ CH(CH ₃) ₂	Cbz	S	450	295
8	CH ₂ C ₆ H ₅	CH ₂ CH ₂ CH(CH ₃) ₂	Cbz	R	10000	
9	<i>o</i> -ClC ₆ H ₄	CH ₂ CH ₂ CH(CH ₃) ₂	Cbz	R	380	227
10	<i>m</i> -ClC ₆ H ₄	CH ₂ CH ₂ CH(CH ₃) ₂	Cbz	R	92	61
11	<i>p</i> -ClC ₆ H ₄	CH ₂ CH ₂ CH(CH ₃) ₂	Cbz	R	10	4.1
12	C ₆ H ₅	CH ₂ CH(CH ₃) ₂	Cbz	R	6	3.2
13	C ₆ H ₅	CH ₂ C ₆ H ₅	Cbz	R	190	125
14	C ₆ H ₅	CH ₂ C ₆ H ₁₁	Cbz	R	14	6.7
15	CH ₃	CH ₂ CH ₂ CH(CH ₃) ₂	CbzAsn ^d	R	100	57
16	CH ₃	CH ₂ CH ₂ CH(CH ₃) ₂	QuiAsn ^e	R	27	13
17	C ₆ H ₅	CH ₂ CH ₂ CH(CH ₃) ₂	CbzAsn	R	2.2	0.5
19	C ₆ H ₅	CH ₂ CH ₂ CH(CH ₃) ₂	QuiAsn	R	1.5	1.0

^a Configuration of the hydroxy group. ^b The positive control was MVT-101 (IC₅₀ = 1.9 ± 0.4 μM). ^c Cbz, carbobenzyloxy. ^d CbzAsn, *N*-Cbz-L-asparagine. ^e QuiAsn, *N*-quinolinyl-2-carboxy-L-asparagine.

A general synthetic route for the preparation of compound **19** is shown in Scheme 1. The pure epoxide **2** was prepared from Cbz-L-phenylalanyl chloromethylketone as previously described.^{8,11} The epoxide was treated with an excess of isoamylamine in refluxing 2-propanol to provide the crystalline amino alcohol **3**. Alternatively, the isoamylamine could be replaced with other primary amines. The amino alcohol **3** was then allowed to react with benzenesulfonyl chloride to generate **6a**. Compounds **4-14** were prepared in a similar manner. Hydrogenation of the Cbz protecting group was readily accomplished, and the resulting free amine **7** could be smoothly coupled to *N*-Cbz-L-asparagine using HOBt and EDC to generate **17**. Deprotection of **17** and coupling to quinaldic acid as the hydroxysuccinimide ester generated **19**. Compound **16** was prepared in a similar manner.

The IC₅₀ values for inhibition of recombinant HIV-1 protease were determined using the spectrofluorometric

Scheme 1^a

^a Reaction conditions: (a) NaBH₄, MeOH/THF (1:1); (b) separate; (c) KOH, EtOH; (d) 20 equiv of isoamylamine; (e) C₆H₅SO₂Cl, Et₃N, CH₂Cl₂; (f) 10% Pd/C, H₂, MeOH; (g) Cbz-L-Asn, HOBT, EDC, DMF; (h) quinoline-2-carboxylic acid hydroxysuccinimide ester.

assay developed by Toth and Marshall and are shown in Table 1.^{12,13}

It was observed that the *in vitro* potency increases significantly as sulfonyl group R₁ is changed from methyl to *n*-propyl to phenyl (compounds 4, 5, and 6a). Replacing the phenyl group with benzyl (compound 8), however, causes a significant reduction in affinity. Introduction of a chlorine atom into the para position of the sulfonamide phenyl ring (11) resulted in a compound of similar potency to the unsubstituted compound (6a). In contrast, the introduction of a chlorine atom into the ortho or meta positions (9 or 10) resulted in a decrease in potency.¹⁴ Several variations at R₂ were investigated (6a, 12, 13, and 14). The compounds with the isoamyl (6a) and cyclohexylmethyl (14) side chains had similar potency, whereas the isobutyl analog (12) exhibited a modest increase in potency. In contrast, the benzyl analog (13) was about 10-fold less active than the corresponding cyclohexylmethyl compound.

With respect to the stereochemistry of the hydroxyl




Figure 1. Structures for a (*R*)-(hydroxyethyl)urea isostere and (*R*)-(hydroxyethyl)amino isostere containing a Cbz group at P2, comparable to 12, and their IC₅₀ values.

group, compounds 6a and 6b demonstrate a clear preference for the *R* alcohol in this series.¹⁵

Replacement of the carbobenzyloxy group with Cbz-L-asparagine led to increased potency (compare compounds 4 and 15 and 6a and 17) and, in the case of 15, the subsequent replacement of the Cbz group with quinaldic acid resulted in an additional increase in binding affinity (16).

These results demonstrate that utilization of the (*R*)-(hydroxyethyl)sulfonamide isostere can provide potent





Figure 2. Stereoview of the binding of **17** to HIV-1 protease. The single-letter amino acid code is used and residues from opposing chains of the dimeric enzyme are labeled a and b; the (*R*)-(hydroxyethyl)sulfonamide inhibitor is drawn with thicker lines. A conserved solvent ligand forms a hydrogen bond (2.76 Å) with the P2 carbonyl oxygen and with the *pro-R* oxygen of the sulfonamide (2.76 Å); the *pro-S* oxygen and amide nitrogen atoms of the sulfonamide moiety do not participate in hydrogen bonding. Some of the atoms of the P1' isoamyl group and P2' phenyl ring are solvent accessible, and three ordered water molecules that lead to the surface of the complex are illustrated.

Table 2. Antiviral Activity of Selected HIV-1 Protease Inhibitors



entry	R ₁	R ₂	R ₃	EC ₅₀ (nM) ^a	TD ₅₀ (nM) ^b
6a	C ₆ H ₅	CH ₂ CH ₂ CH(CH ₃) ₂	Cbz	55	26000
12	C ₆ H ₅	CH ₂ CH(CH ₃) ₂	Cbz	113	8000
16	CH ₃	CH ₂ CH ₂ CH(CH ₃) ₂	QuiAsn ^c	53	45000
19	C ₆ H ₅	CH ₂ CH ₂ CH(CH ₃) ₂	QuiAsn	5	203000

^a Concentration necessary to inhibit 50% HIV-induced cell death. ^b Toxic dose 50% in uninfected cells. ^c QuiAsn, *N*-quinolinyl-2-carboxy-L-asparagine.

inhibitors of the HIV-1 protease, even with a carbobenzyloxy group in the P2 position. This is in contrast to the (*R*)-(hydroxyethyl)urea isostere⁸ and the (*R*)-(hydroxyethyl)amino isostere.¹⁶ For example, **12** has an IC₅₀ = 6 nM, while compounds **20** and **21**, Figure 1, exhibit IC₅₀ values of 112 and 62 nM, respectively, in our enzyme assay.

X-ray crystallography of the enzyme-inhibitor complex with **17** (Figure 2) indicates that the inhibitor binds in an extended conformation. The Cbz group occupies S3, the asparagine is in S2, and the benzyl side chain of the Phe isostere is in S1 as expected. The *N*-isoamyl side chain of the sulfonamide occupies S1' and the aryl ring of the sulfonamide occupies S2' in a normal extended fashion. As expected, the hydroxyl group binds to the catalytic aspartates. The *pro-R* oxygen of the sulfonamide along with the P2/P1 amide carbonyl forms a strong hydrogen bonding array to the structural water molecule found in most enzyme-inhibitor complexes.¹⁷ The *pro-S* oxygen and the amide nitrogen of the sulfonamide do not participate in hydrogen bonding to the enzyme.

Several of these compounds were screened for antiviral activity against the HIV_{IIIB} strain of HIV-1 in a CEM cell based assay.¹⁸ As shown in Table 2, these compounds have excellent antiviral activity and minimal toxicity. There is good correlation between IC₅₀'s and EC₅₀'s in the longer compounds (**16** and **19**), suggesting good cell penetration and stability to the assay conditions.

In conclusion, we have discovered a series of novel and highly potent HIV-1 protease inhibitors, based on the (*R*)-(hydroxyethyl)sulfonamide isostere, which show excellent antiviral properties in vitro. Certain members of this class represent some of the simplest, most potent enzyme inhibitors reported to date.¹⁹

Acknowledgment. The authors would like to acknowledge the continuing support and contributions of Professors Daniel H. Rich (University of Wisconsin at Madison) and Garland R. Marshall (Washington University) to our ongoing efforts to develop HIV-1 protease inhibitors.

Supplementary Material Available: Experimental procedures for the preparation of **19** and its analogues and, also, further details of the biological assays and X-ray crystal structure (10 pages). Ordering information is given on any current masthead page.

References

- (1) (a) Pearl, L. H.; Taylor, W. R. A Structural Model for the Retroviral Proteases. *Nature* **1987**, *329*, 351-354. (b) Power, M. D.; Marx, P. A.; Bryant, M. L.; Gardner, M. B.; Barr, P. J.; Luciw, P. A. Nucleotide Sequence of SRV-1, a Type D Simian Acquired Immune Deficiency Syndrome Virus. *Science* **1986**, *231*, 1567-1572. (c) Kramer, R. A.; Schaber, M. D.; Skalka, A. M.; Ganguly, K.; Wong-Staal, F.; Reddy, E. P. HTLV-III gag Protein is Processed in Yeast Cells by the Virus pol-Protease. *Science* **1986**, *231*, 1580-1584. (d) Ratner, L.; Haseltine, W.; Patarca, R.; Livak, K. J.; Starcich, B.; Josephs, S. F.; Doran, E. R.; Rafalski, J. A.; Whitehorn, E. A.; Baumeister, K.; Ivanoff, L.; Petteway, S. R., Jr.; Pearson, M. L.; Lautenberger, J. A.; Pappas, T. S.; Ghayeb, J.; Chang, N. T.; Gallo, R. C.; Wong-Staal, F. Complete Nucleotide Sequence of the AIDS Virus, HTLV-III. *Nature* **1985**, *313*, 277-284. (e) Wain-Hobson, S.; Sonigo, P.; Danos, O.; Cole, S.; Alizon, M. Nucleoside Sequence of the AIDS Virus, LAV Cell **1985**, *40*, 9-17. (f) Muesing, M. A.; Smith, D. H.; Cabradilla, C. D.; Benton, C. V.; Lasky, L. A.; Capon, D. J. Nucleic Acid Structure and Expression of the Human AIDS/Lymphadenopathy Retrovirus. *Nature* **1985**, *313*, 450-458.
- (2) Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A. F.; Scolnick, E. M.; Sigal, I. Active Human Immunodeficiency Virus Protease is Required for Viral Infectivity. *Proc. Natl. Acad. Sci. U.S.A.* **1986**, *85*, 4686-4690.
- (3) Tomasselli, A. G.; Howe, W. J.; Sawyer, T. K.; Wlodawer, A.; Heinrichson, R. L. The Complexities of AIDS: An Assessment of the HIV Protease as a Therapeutic Target. *Chimicaoggi* **1991** (May), 6-27.
- (4) Debouck, C. The HIV-1 Protease as a Therapeutic Target for AIDS. *AIDS Res. Human Retroviruses* **1992**, *8* (2), 153-164.
- (5) Norbeck, D. W.; Kempf, D. J. HIV Protease Inhibitors. *Annual Reports in Medicinal Chemistry*; Bristol, J. A., Ed.; Academic Press: New York, 1991; Vol. 26, pp 141-150.

- (6) (a) Huff, J. R. HIV Protease: A Novel Chemotherapeutic Target for AIDS. *J. Med. Chem.* **1991**, *34*, 2305–2314. (b) Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. *Advances in Pharmacology*; August, J. T., Anders, M. W., Murad, F., Eds.; Academic Press: San Diego, 1994; Vol. 25, pp 399–454.
- (7) Martin, J. A. Recent Advances in the Design of HIV Protease Inhibitors. *Antiviral Res.* **1992**, *17*, 265–278.
- (8) Getman, D. P.; DeCrescenzo, G. A.; Heintz, R. M.; Reed, K. L.; Talley, J. J.; Bryant, M. L.; Clare, M.; Houseman, K. A.; Marr, J. J.; Mueller, R. A.; Vazquez, M. L.; Shieh, H.-S.; Stallings, W. C.; Stegeman, R. A. Discovery of a Novel Class Of Potent HIV-1 Protease Inhibitors Containing the (R)-(Hydroxyethyl)urea Isostere. *J. Med. Chem.* **1993**, *36*, 288–291.
- (9) (a) Moree, W. J.; van Gent, L. C.; van der Marel, G. A.; Liskamp, M. J. Synthesis of Peptides Containing a Sulfinamide or a Sulfonamide Transition State Isostere. *Tetrahedron* **1993**, *49*, 1133–1150. (b) Moree, W. J.; van der Marel, G. A.; Liskamp, R. M. J. Synthesis of Peptides Containing the β -Substituted Aminoethane Sulfinamide or Sulfonamide Transition-state Isostere Derived from Amino Acids. *Tetrahedron Lett.* **1992**, *33*, 6389–6392. (c) Moree, W. J.; van der Marel, G. A.; Liskamp, R. M. J. Peptides Containing A Sulfinamide or Sulfonamide Moiety: New Transition-state Analogues. *Tetrahedron Lett.* **1991**, *32*, 409–412. (d) Spaltenstein, A.; Leban, J. J.; Furfine, E. S. Synthesis of C₂-Symmetric HIV-Protease Inhibitors With Sulfur-Containing Central Units. *Tetrahedron Lett.* **1993**, *34*, 1457–1460.
- (10) (a) McLeod, D. A.; Brinkworth, R. I.; Ashley, J. A.; Janda, K. D.; Wirsching, P. Phosphoramidates and Phosphoramidate Esters as HIV-1 Protease Inhibitors. *Bioorg. Med. Chem. Lett.* **1991**, *1*, 653–658. (b) Peyman, A.; Budt, K.-H.; Spanig, J.; Stowasser, B.; Ruppert, D. C₂-Symmetric Phosphinic Acid Inhibitors of HIV Protease. *Tetrahedron Lett.* **1992**, *33*, 4549–4552. Stowasser, B.; Budt, K.-H.; Jian-Qi, L.; Peyman, A.; Ruppert, D. New Hybrid Transition State Analog Inhibitors of HIV Protease with Peripheral C₂-Symmetry. *Tetrahedron Lett.* **1992**, *33*, 6625–6628.
- (11) Luly, J. R.; Dellaria, J. F.; Plattner, J. J.; Soderquist, J. L.; Yi, N. J. A Synthesis of Protected Aminoalkyl Epoxides from α -Amino Acids. *J. Org. Chem.* **1987**, *52* (8), 1487–1492.
- (12) Toth, M. V.; Marshall, G. R. A Simple, Continuous Fluorometric Assay for HIV Protease. *Int. J. Pept. Protein Res.* **1990**, *36*, 544–550. The substrate is 2-(aminobenzoyl)-Thr-Ile-Nle-Phe(*p*-NO₂)-Gln-ArgNH₂ ($K_m = 37 \mu\text{M}$) and the positive control is MVT-101 (Ac-Thr-Ile-Nle[CH₂NH]Nle-Gln-ArgNH₂). For related aspartyl proteases, the inhibition observed for **21** was porcine pepsin (IC₅₀ = 19 μM), bovine cathepsin D (IC₅₀ = 10.5 μM) and human renin (16% at 10 μM , 28% at 100 μM).
- (13) K_i 's were determined using the program FastKi, written by Dr. Petr Kuzmic, Biokin, Ltd., P.O. Box 9240, Madison, WI 53715.
- (14) Similar results were observed with other substituents, for example, methoxy and nitro (data not shown).
- (15) For examples of *R* vs *S* alcohol comparisons in other inhibitor series, see ref 8 and references contained therein.
- (16) Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Krohn, A.; Lambert, R. W.; Merrett, J. H.; Mills, J. S.; Parkes, K. E. B.; Redshaw, S.; Ritchie, A. J.; Taylor, D. L.; Thomas, G. J.; Machin, P. J. Rational Design of Peptide-Based HIV Protease Inhibitors. *Science* **1990**, *248*, 358–361.
- (17) X-ray crystallography of other inhibitor complexes show this binding mode to be typical of the (*R*)-(hydroxyethyl)arylsulfonamide isostere.
- (18) Drug candidates were evaluated against the HIV_{III}B strain of HIV-1 in CEM cells at a multiplicity of infection of 0.1 for their ability to prevent HIV-induced cell death. Compounds were evaluated in triplicate at varying doses and compared to (1) untreated, uninfected cell control samples, (2) drug-treated, uninfected cell toxicity control samples, and (3) untreated, infected virus control samples. Drug was added on days 0, 2, and 5, the assay terminated on day 7, and cell death assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). This assay detects drug induced suppression of viral CPE, as well as drug cytotoxicity, by measuring the generation of MTT-formazan by surviving cells. 3'-Azido-3'-deoxythymidine (AZT) and 2',3'-dideoxyinosine (DDI) were included as positive control compounds, and typically provided EC₅₀ values of 0.001–0.005 $\mu\text{g}/\text{mL}$ and 0.25–1.0 $\mu\text{g}/\text{mL}$, respectively. For comparison, Ro 31-8959, prepared in-house, exhibited an EC₅₀ = 8 nM in this assay.¹⁶
- (19) For other examples of relatively simple potent HIV protease inhibitors, see: (a) Thaisrivongs, S.; Tomich, P. K.; Watenpaugh, K. D.; Chong, K.-T.; Howe, W. J.; Yang, C.-P.; Strohbach, J. W.; Turner, S. R.; McGrath, J. P.; Bohanon, M. J.; Lynn, J. C.; Mulichak, A. M.; Spinelli, P. A.; Hinshaw, R. R.; Pagano, P. J.; Moon, J. B.; Ruwart, M. J.; Wilkinson, K. F.; Rush, B. D.; Zipp, G. L.; Dalga, R. J.; Schwende, F. J.; Howard, G. M.; Padbury, G. E.; Toth, L. N.; Zhao, Z.; Koeplinger, K. A.; Kakuk, T. J.; Cole, S. L.; Zaya, R. M.; Piper, R. C.; Jeffrey, P. Structure-Based Design of HIV Protease Inhibitors: 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Non-peptidic Inhibitors. *J. Med. Chem.* **1994**, *7*, 3200–3204. (b) Tung, R. Design and Optimization of Potent, Orally Active HIV Aspartyl Protease Inhibitors, presented at VI International Antiviral Symposium, June 7–10, 1994, Nice, France.

JM940754M